Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
165
resultados
Última actualización
16/10/2026 [06:58:00]
Resumen de: US20260191892A1
0000 The present invention provides a pharmaceutical composition including berberine, militarine, liquiritin, curcumin and atractylenolide III. The pharmaceutical composition is proven to be effective on ulcerative colitis modulating targets including MAOA, MAPK14, AHR, PTGS2, PLA2G1B, and ALOX5. The present invention further provides a method of preparing the pharmaceutical composition including optimization of extraction, determining the quality markers, and optimization of temperature. The present invention further provides a method of treating or alleviating ulcerative colitis.
Resumen de: US20260193242A1
0000 The present disclosure provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R to R<3 >and X are defined herein; pharmaceutical compositions; dosage forms comprising the compounds or pharmaceutical compositions, and methods of treating inflammation, decreasing inflammation, decreasing an inflammatory marker, treating inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, or treating sepsis in a subject in need thereof, comprising administering the compounds, pharmaceutical compositions or dosage forms disclosed herein to a subject in need thereof.
0000
Resumen de: CN122348053A
The invention provides a radiomics and clinical feature identification model based on CT small intestine radiography, and relates to the technical field of medical treatment. The identification model comprises data of clinical data, laboratory examination, imaging examination, enteroscopy and pathological examination, imaging omics for extracting intestinal wall and mesenteric fat features based on CT small intestine radiography, and an identification diagnosis model for Crohn's disease and intestinal tuberculosis is constructed through machine learning. By integrating clinical features and radiomics parameters of CT small intestine radiography, a differential diagnosis model of Crohn's disease and intestinal tuberculosis is constructed, and the differential diagnosis model is remarkably superior to a single model. Image omics features reveal essential differences of the two diseases on intestinal wall and mesenteric fat textures. The constructed column diagram provides a convenient visual tool for clinic, and is particularly suitable for accurate diagnosis in areas with high tuberculosis incidence.
Resumen de: CN122337628A
The invention belongs to the technical field of medical diagnosis assistance, and provides an inflammatory bowel disease assessment method and system.The method includes the steps that biological sample data of a target object is obtained and preprocessed to standardize index data, and the index data is obtained; and calculating multiple scores representing the individual state of the target object based on the preprocessed biological sample data, and constructing a comprehensive evaluation index for quantitatively evaluating the inflammatory bowel disease of the target object based on the scores. According to the scheme provided by the invention, a multi-dimensional comprehensive evaluation index is constructed by integrating multiple index data, so that the pathophysiological essence of the inflammatory bowel disease can be comprehensively and accurately reflected, misdiagnosis or missed diagnosis caused by single-dimensional evaluation is effectively avoided, and the diagnosis accuracy is improved. And a non-invasive, convenient and standardized technical solution is provided for diagnosis, illness monitoring and curative effect evaluation of the inflammatory bowel disease.
Resumen de: CN122337675A
The invention provides a clinical prediction model of anal fistula occurrence probability of a Crohn disease patient and a design method, and belongs to the technical field of clinical medicine. The risk prediction model comprises: an input module receiving patient parameter indexes composed of age during diagnosis, biological agent mode switching and Monte's performance typing during primary definite diagnosis; the processing module is connected with the input module and is used for calculating the evaluation and prediction probability of the anal fistula of the patient suffering from the Crohn disease according to the following formula on the basis of the age during diagnosis, the biological agent mode switching and the Monte performance typing data during primary definite diagnosis; the output module is connected with the processing module and outputs the anal fistula risk probability, obtained by the risk prediction model, of the patient suffering from the Rohn disease. And respectively verifying the prediction model in the training set and the verification set by adopting the area under the curve of the working characteristic curve of the subject and the calibration curve so as to judge the distinction degree and the calibration degree of the prediction model. The risk of anal fistula of a patient suffering from Crohn's disease can be accurately predicted before treatment.
Resumen de: CN122337553A
The invention discloses a diagnosis and treatment path recommendation method based on IBS multi-dimensional data, and relates to the technical field of intelligent diagnosis and treatment, and the method comprises the following steps: S1, constructing an IBS treatment scheme library which comprises standardized treatment schemes corresponding to different diagnosis types and different disease severity degrees of IBS, the standardized treatment schemes at least comprise review suggestions, drug recommendation, probiotic recommendation and nursing guidance, and each treatment scheme is associated with a corresponding IBS multi-dimensional data feature threshold. According to the diagnosis and treatment path recommendation method based on the IBS multi-dimensional data, the limitation of single diagnosis data dimension in the prior art is broken through, four core dimensions of symptom data, physical sign data, laboratory examination data and medical history data of a patient are comprehensively integrated, and the symptom data is ensured to be free of omission by combining dual modes of patient autonomous filling and reporting and doctor inquiry; objectivity of physical sign data is guaranteed through professional medical equipment, laboratory inspection data are synchronously obtained from a hospital inspection system, and errors are reduced.
Resumen de: MX2026003012A
The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1 A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.
Resumen de: CN122326775A
The invention relates to a method for analyzing a relationship between intestinal microbiota and an emotional symptom of an IBS patient. The method comprises the following steps: determining a causal relationship between the intestinal microbiota and the emotional symptom of the IBS patient; determining that the emotional symptom is caused by reduction of abundance of A. shahii in the intestinal microbiota; determining that the emotional symptom is caused by the reduction of indole produced by metabolism of the intestinal microbiota, and the reduction of indole is caused by the reduction of abundance of A. shahii; determining that the emotional symptom is caused by the decrease of TnAse generated by the intestinal microbiota, the decrease of TnAse is caused by the decrease of abundance of A. shahii, and the decrease of indole is caused by the decrease of TnAse; determining that the emotional symptom is caused by the weakening of AhR signal transduction in the vDG of the IBS patient, and the weakening of AhR signal transduction is caused by the reduction of indole; and determining that the emotional symptoms are caused by the weakening of vDG granular cell viability and the weakening of the vDG granular cell viability is caused by the weakening of AhR signal transduction, thereby obtaining an analysis result that the intestinal microbiota regulates and controls the emotional symptoms through the A. shahii-TnAse-indole-AhR-vDG signal pathway.
Resumen de: US20260185998A1
Methods of diagnosing Crohn's disease and ulcerative colitis in subjects is provided based on the determination of metabolites in urine samples, such as serine, hypoxanthine, kynurenine, threonine, indoxylsulfate, phenylacetylglutamine, 5-hydroxy-6-indolyl-O-sulfate, 5-(δ-carboxybutyl) homocysteine, sialic acid, guanidinosuccinic acid (GSA), glutamyl(iso) leucine, trigonelline, cresol sulfate, an anion having m/z: RMT: polarity of 345.1553:0.770: n, aminohippurate: GSA ratiometric biomarker, unknown anion (160.0615:0.830: n): tyrosine ratiometric biomarker and GSA×Tyr: AHA×(an anion having m/z: RMT: polarity of 160.0615:0.830: n) ratiometric biomarker.
Resumen de: CN122297639A
The invention provides an application of NUCB1 in preventing and/or treating autoimmune diseases, and particularly provides an application of an NUCB1 gene, or a protein thereof or an accelerant thereof in preparing a composition or a preparation, and the composition or the preparation is used for preventing and/or treating the autoimmune diseases. The NUCB1 gene, or the protein thereof, or the promoter thereof can significantly prevent and/or treat autoimmune diseases, especially can effectively treat systemic lupus erythematosus, atopic dermatitis, rheumatoid arthritis, psoriasis, multiple sclerosis or Crohn's disease.
Resumen de: CN122303417A
The present invention relates to anti-TREM-1 antibodies and uses thereof, and provides methods of identifying a subject suitable for treatment with an anti-TREM-1 antibody, i.e., an antagonistic anti-TREM-1 antibody, comprising measuring the expression level of a TREM-1 related gene. Also disclosed herein are methods of determining the efficacy of an anti-TREM-1 antibody, comprising measuring the expression level of a TREM-1-related gene. Also disclosed are methods of identifying non-responders to care treatment criteria and methods of treating a disease or disorder (e.g., inflammatory bowel disease) with an anti-TREM-1 antibody.
Resumen de: WO2024254399A2
The present disclosure relates to anti-ToH1 antibodies, methods of generating anti-ToH1 antibodies, and methods of use of anti-ToH1 antibodies for diagnosis and treatment of microbial disease and/or chronic inflammatory disease, including microbial infection and microbe-associated chronic inflammatory conditions.
Resumen de: NZ785937A
Methods of treating patients having inflammatory bowel disease (IBD) or primary sclerosing cholangitis (PSC) are provided herein. Patients heterozygous or homozygous for an MST1 variant nucleic acid molecule encoding Arg651STOP are treated by administration of an MST1 protein.
Resumen de: CN122278770A
The invention relates to a method for screening drugs for diseases closely related to unmarked G-protein coupled receptors (GPCR), in particular to an unmarked cell screening model of a GPR183 receptor and application of the unmarked cell screening model in preparation of drugs. And the unmarked cell screening model is a stably transfected cell strain CHO-K1-GPR183 with high expression of a GPR183 receptor. The GPR183 receptor stimulant compound N-demethylated nuciferine is obtained by screening through the GPR183 cell screening model established in the invention. At present, researches show that the GPR183 receptor is closely related to the occurrence and development of neuroinflammation/autoimmune diseases such as multiple sclerosis, colitis, type I diabetes and arthritis, cancers and metabolic diseases, so that a seedling compound can be provided for the development of medicines for related diseases.
Resumen de: WO2026136763A1
Provided are methods of generating a polygenic score (PGS) to identify or predict interleukin- 18 (IL- 18) driven disease in a subject, along with methods of treating subjects with various diseases and conditions, such as inflammatory bowel disease, determined to have IL- 18 driven disease or inflammasome-mediated disease based on a PGS.
Resumen de: WO2025038942A1
Disclosed are methods for imaging inflammation associated with inflammatory bowel disease (IBD), including administering to a subject a prostate-specific membrane antigen (PSMA)-targeted imaging agent and taking an image.
Resumen de: CN122259877A
The invention discloses application of TLR8 in preparation of a product for diagnosing and treating ulcerative colitis, and belongs to the technical field of biological medicines. The invention provides an application of TLR8 in preparation of an ulcerative colitis diagnostic product, the diagnostic product is used for detecting the expression level of TLR8 in a peripheral blood sample, and the diagnostic product comprises a detection reagent, a detection kit and a detection chip; meanwhile, the invention provides application of TLR8 in preparation and/or screening of drugs for treating ulcerative colitis and application of a TLR8 inhibitor in preparation of drugs for treating or relieving ulcerative colitis. The medicine can be used for reducing the phosphorylation level of p65 in an NF-kappa B pathway by inhibiting the expression of TLR8, so that the intestinal inflammatory response is relieved. The invention clarifies the association between TLR8 and ulcerative colitis, provides a new target and detection means for the early diagnosis of ulcerative colitis, provides a new idea and drug research and development direction for the treatment of the disease, and has important clinical application value and industrialization prospect.
Resumen de: CN122270562A
The present disclosure relates generally to methods for treating inflammatory bowel disease ("IBD", such as Crohn's disease or ulcerative colitis) in a patient. More specifically, the present disclosure relates to a method for selecting a therapy for treating a patient with IBD. In embodiments, the foregoing can also be used to assess the severity of the IBD. The predictive aspects of the methods are capable of facilitating and accelerating the identification and stratification of IBD patient populations that are reactive to treatment with RIPK2 inhibitors. The foregoing methods can further comprise treating the IBD by administering a RIPK2 inhibitor to the patient.
Resumen de: WO2024252267A1
The invention relates to a method and kit for the diagnosis of Inflammatory Bowel Disease (IBD) in a subject. The diagnostic method is based on the detection of fecal Calprotectin and at least one further fecal biomarker selected from PGRP-S and MMP-8 in a stool sample from the subject. In a preferred embodiment, the fecal biomarkers concentration data obtained are analyzed and classified as affected by IBD or not affected by IBD by a supervised machine learning diagnosis model.
Resumen de: WO2024240709A1
The present invention relates to methods of immunoassay for detecting HNE-generated fragments of the α1 chain of type III collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. The present invention also relates to monoclonal antibodies and assay kits for use in said methods of immunoassay.
Resumen de: CN122229982A
The invention belongs to the technical field of marine product function application, functional food and biology, and discloses oyster oligopeptide for relieving dextran sodium sulfate (DSS) induced ulcerative colitis and a preparation method and application thereof. A DSS induced human normal colonic epithelial cell injury model is taken as a guide, oyster meat is subjected to enzymolysis, degreasing and alcohol precipitation preparation and purification to obtain oyster zymolyte, two oyster peptides are obtained through identification, bioinformatics screening and synthesis verification, and the amino acid sequences are shown as SEQ ID NO.1-2. The oyster oligopeptide has relatively strong antioxidant and anti-inflammatory activity, can effectively relieve DSS-induced NCM460 cell injury, has an effect superior to that of a positive control 5-aminosalicylic acid, and can be used for preparing medicines for relieving ulcerative colitis and foods and health-care products for adjuvant therapy of ulcerative colitis.
Resumen de: CN122245701A
The invention provides an inflammatory bowel disease subtype diagnosis model and a construction method thereof, and the diagnosis model is characterized in that an RNA editing characteristic spectrum capable of specifically distinguishing Crohn's disease and ulcerative colitis is extracted from a PBMC sample obtained by minimally invasive acquisition through a set of innovative bioinformatics flow, and the RNA editing characteristic spectrum is used for constructing the inflammatory bowel disease subtype diagnosis model. And a machine learning model is constructed and trained by using the characteristic spectrum, and finally accurate and automatic diagnosis of the IBD subtype is realized.
Nº publicación: WO2026128869A1 18/06/2026
Solicitante:
PALISADE BIO INC [US]
PALISADE BIO, INC.
Resumen de: WO2026128869A1
Personalized methods of determining a reference PDE4 Inhibitor Resistance Metric for treating a future patient in need of treatment, and methods of treating a subject with an inflammatory bowel disease are provided.
BOPI
Sede Electrónica
